Coherus BioSciences Inc
NASDAQ:CHRS
Coherus BioSciences Inc
Revenue
Coherus BioSciences Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Coherus BioSciences Inc
NASDAQ:CHRS
|
Revenue
$257.2m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
58%
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
Coherus BioSciences Inc
Revenue Breakdown
Breakdown by Geography
Coherus BioSciences Inc
Breakdown by Segments
Coherus BioSciences Inc
Total Revenue:
257.2m
USD
|
Product Revenue:
256.6m
USD
|
Other:
664k
USD
|
See Also
What is Coherus BioSciences Inc's Revenue?
Revenue
257.2m
USD
Based on the financial report for Dec 31, 2023, Coherus BioSciences Inc's Revenue amounts to 257.2m USD.
What is Coherus BioSciences Inc's Revenue growth rate?
Revenue CAGR 10Y
58%
Over the last year, the Revenue growth was 22%. The average annual Revenue growth rates for Coherus BioSciences Inc have been -19% over the past three years , and 58% over the past ten years .